These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 17446118

  • 1. Structured to reduce the mitogenicity of anti-CD3 antibody based on computer-guided molecular design.
    Lv M, Li Y, Yu M, Sun Y, Lin Z, Qiao C, Luo Q, Gu X, Huang Y, Feng J, Shen B.
    Int J Biochem Cell Biol; 2007; 39(6):1142-55. PubMed ID: 17446118
    [Abstract] [Full Text] [Related]

  • 2. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.
    Li B, Wang H, Dai J, Ji J, Qian W, Zhang D, Hou S, Guo Y.
    Immunology; 2005 Dec; 116(4):487-98. PubMed ID: 16313362
    [Abstract] [Full Text] [Related]

  • 3. The novel non-mitogenic anti-CD3 antibody, mini-yCD3, delivers a partial TCR signal.
    Lv M, Qiao C, Lin Z, Yu M, Hou C, Sun Y, Li Y, Feng J, Shen B.
    Int Immunopharmacol; 2010 Feb; 10(2):200-6. PubMed ID: 19913640
    [Abstract] [Full Text] [Related]

  • 4. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
    Le Gall F, Reusch U, Moldenhauer G, Little M, Kipriyanov SM.
    J Immunol Methods; 2004 Feb 01; 285(1):111-27. PubMed ID: 14871540
    [Abstract] [Full Text] [Related]

  • 5. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J, Davis J, Bracht M, Carton J, Armstrong J, Gao W, Scallon B, Fung R, Emmell E, Zimmerman M, Griswold DE, Li L.
    Int Immunopharmacol; 2006 Jun 01; 6(6):880-91. PubMed ID: 16644473
    [Abstract] [Full Text] [Related]

  • 6. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
    Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H.
    Eur J Immunol; 1993 Feb 01; 23(2):403-11. PubMed ID: 8436176
    [Abstract] [Full Text] [Related]

  • 7. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
    Alegre ML, Tso JY, Sattar HA, Smith J, Desalle F, Cole M, Bluestone JA.
    J Immunol; 1995 Aug 01; 155(3):1544-55. PubMed ID: 7636216
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
    Cole MS, Anasetti C, Tso JY.
    J Immunol; 1997 Oct 01; 159(7):3613-21. PubMed ID: 9317161
    [Abstract] [Full Text] [Related]

  • 10. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
    Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA.
    Transplantation; 1994 Jun 15; 57(11):1537-43. PubMed ID: 8009586
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
    Abbs IC, Clark M, Waldmann H, Chatenoud L, Koffman CG, Sacks SH.
    Ther Immunol; 1994 Dec 15; 1(6):325-31. PubMed ID: 7584508
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes.
    Malviya G, D'Alessandria C, Bonanno E, Vexler V, Massari R, Trotta C, Scopinaro F, Dierckx R, Signore A.
    J Nucl Med; 2009 Oct 15; 50(10):1683-91. PubMed ID: 19759100
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.
    Vossen AC, Tibbe GJ, Kroos MJ, van de Winkel JG, Benner R, Savelkoul HF.
    Eur J Immunol; 1995 Jun 15; 25(6):1492-6. PubMed ID: 7614975
    [Abstract] [Full Text] [Related]

  • 18. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
    Richards J, Auger J, Peace D, Gale D, Michel J, Koons A, Haverty T, Zivin R, Jolliffe L, Bluestone JA.
    Cancer Res; 1999 May 01; 59(9):2096-101. PubMed ID: 10232594
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.